The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
about
Mepolizumab versus placebo for asthmaOmalizumab for asthma in adults and childrenAnti-IgE for chronic asthma in adults and childrenAnti-IgE for chronic asthma in adults and childrenUpdate in asthma 2009The Therapeutic Potential of Targeting Cytokine Alarmins to Treat Allergic Airway InflammationA novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthmaDevelopment of New Therapies for Severe AsthmaRational protein design: developing next-generation biological therapeutics and nanobiotechnological toolsMonoclonal antibodies and other biologic agents in the treatment of asthmaThe immunology of asthma: Asthma phenotypes and their implications for personalized treatment.Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.Asthma outcomes: exacerbationsOmalizumab: a novel therapy for allergic asthma.Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a reviewThe role of omalizumab in the treatment of severe allergic asthma.Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes.Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.Omalizumab: the evidence for its place in the treatment of allergic asthmaOmalizumab in the treatment of asthma.Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma.Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.Omalizumab: Practical considerations regarding the risk of anaphylaxis.Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.Anti-IgE treatment: an update.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescentsOmalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.From IgE to anti-IgE: where do we stand?Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.Is there a role for treatment of asthma with omalizumab?Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody.Update on optimal use of omalizumab in management of asthma.Management of asthma in adults: current therapy and future directions
P2860
Q24186306-7B257D27-A6D4-458C-A981-9E9F6F8BAF45Q24201145-98F8BBA3-2AF4-405D-990D-6421EE32C5C3Q24246484-00D5B681-F7A9-41F8-A818-D6818417324DQ24247152-19406212-3827-47B1-BAE6-1FD1FA1EECFDQ24599763-DC7512EB-1801-4C45-B9A5-52E1DBA8A3D8Q26744623-9D306CE5-F1E3-485E-BF04-421DB344D4D5Q27689386-4CEC0AF6-8BA5-4743-94A4-5E67214F544DQ28077546-E3B7CC02-511A-4D66-8284-DB2ECA619F72Q28250420-33A6E132-6EE8-4468-8CBF-A3C660A55D93Q28270037-D0923E66-4A92-45CD-8B97-7496C1B7D9B1Q30276175-817EF16B-3E1E-4C35-AE1C-E047491C1A42Q30360362-0B352CB3-EB8B-42E0-9277-6F8A95CAC640Q30421935-F9DA6FD1-3486-4141-AC33-A42A180F36D2Q30433722-F84C1B52-34C5-411A-A0B8-39F2F607AA74Q30444397-3DB953EE-3F2B-49E6-A0E4-AA046621B9D1Q30801642-6C1DAC67-21A9-4555-99F0-42DE617F55DBQ33591890-6BF62F7F-EDD1-481B-939E-BED82F4C859BQ33758358-D7FC8CD5-7F2D-458E-9FC9-CC34D17C4121Q33785112-3F0D2542-0838-4689-ABD5-BF56D1AE9EFFQ33786076-3F3BEA5E-4548-42E7-A95B-D6D87B2E8109Q33973970-5E343FFA-FECC-4528-A94A-FFED796F9621Q34029374-BFF55176-0CD9-4303-9433-D771AD0DF600Q34336901-110CA844-7AB0-4602-B2FF-F876DD155922Q34388348-2643DEAC-DA0C-4E61-A547-D29A2C8BBF9EQ34412092-8E88C448-6891-445A-8580-6A9C6695262DQ34426639-A12F38E6-1B7F-426A-8B74-10913A13350CQ34427691-80BBC7F2-31BE-423A-8B7B-3195B6466761Q34458962-AAA8B2BF-9B44-45AD-AB6F-8A4501D97958Q34623856-A0A23157-C6F8-4D09-91DF-0F0DFF7D336CQ34625206-B1BE1B06-2B20-4F0A-B174-A13CEC573171Q34627039-C9D241BB-447C-4349-ABF5-82159A18CC73Q34627140-D7F3AD0F-D31D-4D37-9384-A8FDCC0F6737Q34660055-B306C341-0D69-4949-912D-F5644037FD93Q34929214-ABEF3BE4-446D-426B-8EC2-6F466A50F782Q34979344-D6DD5C79-8B7F-4E56-B014-9ED7F0FC8E71Q35032157-343732D0-85B5-4828-867D-D00163D3F3A0Q35040868-9933CD6C-8493-4BE5-989F-1BFCEA821C84Q35093643-5518C3C9-8425-40AB-8FE5-5A736C2F68C6Q35117827-F0B0346F-F42C-4368-BB86-D96B0EEC3250Q35143482-64056B62-5689-4CA5-A808-C4C92F293D62
P2860
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
The anti-IgE antibody omalizum ...... rement in allergic asthmatics.
@en
The anti-IgE antibody omalizum ...... rement in allergic asthmatics.
@nl
type
label
The anti-IgE antibody omalizum ...... rement in allergic asthmatics.
@en
The anti-IgE antibody omalizum ...... rement in allergic asthmatics.
@nl
prefLabel
The anti-IgE antibody omalizum ...... rement in allergic asthmatics.
@en
The anti-IgE antibody omalizum ...... rement in allergic asthmatics.
@nl
P2093
P1476
The anti-IgE antibody omalizum ...... rement in allergic asthmatics.
@en
P2093
G Della Cioppa
J Thirlwell
P304
P356
10.1183/09031936.01.00092101
P577
2001-08-01T00:00:00Z